Summary Background Glucagon-like peptide-1 (GLP-1) receptor agonists are effective
glucose-lowering drugs. Findings from cardiovascular outcome trials showed cardiovascular …

Praise for the Second Edition:"… this is a useful, comprehensive compendium of almost
every possible sample size formula. The strong organization and carefully defined formulae …

Background The cardiovascular effects of adding once-weekly treatment with exenatide to
usual care in patients with type 2 diabetes are unknown. Methods We randomly assigned …

Background The effect of intensified platelet inhibition for patients with unstable angina or
myocardial infarction without ST-segment elevation who do not undergo revascularization …

Background Vorapaxar is a new oral protease-activated–receptor 1 (PAR-1) antagonist that
inhibits thrombin-induced platelet activation. Methods In this multinational, double-blind …

Background—We sought to define the factors associated with the occurrence of stroke and
systemic embolism in a large, international atrial fibrillation (AF) trial. Methods and Results …

Background: We examined the relation of maximal in‐hospital diuretic dose to weight loss,
changes in renal function, and mortality in hospitalised heart failure (HF) patients. Methods …

Background—Nonvalvular atrial fibrillation is common in elderly patients, who face an
elevated risk of stroke but difficulty sustaining warfarin treatment. The oral factor Xa inhibitor …

BACKGROUND & AIMS:: A single nucleotide polymorphism (SNP) upstream of the IL28B
gene has been associated with response of patients with chronic hepatitis C to therapy with …

Aim Anticoagulation prophylaxis for stroke is recommended for at-risk patients with either
persistent or paroxysmal atrial fibrillation (AF). We compared outcomes in patients with …